SPRY
ARS Pharmaceuticals, Inc. (SPRY) 10Y Growth Potential Analysis (2026)
Overall Score
Growth Runway
Revenue base remains small, with revenue per share at 0.9969 and market cap only about $599M, leaving room for growth if the pipeline scales.
Gross margin is still high at 77.1%, which supports operating leverage if commercialization improves.
Profitability
Margins remain deeply negative, with operating margin at -204.5% and net margin at -200.0%.
Returns on capital are still very poor, including ROIC at -85.0% and ROE at -153.6%.
Financial Health
Liquidity is strong, with a current ratio of 4.94 and quick ratio of 4.77.
The balance sheet is manageable for now, with debt-to-equity at 1.57 and cash per share at 2.02.
Cash Generation
Cash flow remains negative, with free cash flow per share at -1.77 and operating cash flow per share at -1.76.
Free cash flow yield is still negative at -29.3%, indicating the business is not self-funding yet.
Valuation
The stock still trades at a premium growth multiple, with EV/sales at 6.78 and price/sales at 6.05.
Negative earnings and cash flow keep traditional valuation metrics distorted, limiting confidence in the current multiple.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on ARS Pharmaceuticals, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

